Menu

Lung Cancer (LC)

Lung Cancer is among the most common types of cancer in Germany. The high mortality rate is often due to diagnosis at a late stage: 40 % of Non-Small Cell Lung Cancer (NSCLC) patients present with metastases at the time of diagnosis. Advances in molecular tumor analysis have led to new opportunities to develop targeted therapies that act on specific molecular targets of the cancer cell. Besides chemotherapy and targeted therapy, immunotherapy has gained significance as the third main pillar of systemic therapy. Immune checkpoint inhibitors unmask the cancer cells and enhance the body’s immune response against malignant cells. Today, combined treatment approaches in precision medicine enable the application of the most effective treatment regimen for each patient. However, not all patients respond to targeted therapy or immunotherapy. Therefore, an important research goal is the identification of predictive markers indicating clinical response or potential treatment failure, for example through evidence of genetic tumor material towards biomarker-directed precision medicine.

Scientific Coordinators of the Disease Area

Prof. Dr. Rajkumar Savai (UGMLC)
Prof. Dr. Michael Thomas (TLRC)

Administrative Coordinator of the Disease Area

Dr. Birgit Teucher (TLRC)

Participating DZL Partner Sites

all

News about Lung Cancer

17. October 2021

Current Issue of the DZG Magazine SYNERGIE Published

In the current issue of SYNERGIE, the German Centers for Health Research (DZG) show how widespread diseases can be treated more precisely through personally tailored therapies.
Read More
12. April 2021

DZL Funds Four More Clinical Trials – Significant Contribution to Translational Research

Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be funded as of 2021.
Read More
1. February 2021

Extended analysis of tumour DNA in patients’ blood could improve therapy control in lung cancer

Analysing copy number variations (CNVs) of tumour DNA extracted from blood samples of patients with ALK-positive non-small-cell lung cancer can provide valuable information on therapy response and has the potential to improve therapy control.
Read More
All Lung Cancer news
chevron-down